Theravance Inc. (THRX)
-NasdaqGS 36.24 
0.54(1.47%) May 24, 4:00PM EDT|After Hours
:
36.25 0.01 (0.02%) May 24, 4:35PM EDT
| Prev Close: | 36.78 |
|---|
| Open: | 36.62 |
|---|
| Bid: | 33.00 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 47.67 |
|---|
| Beta: | 1.89 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 36.04 - 36.62 |
|---|
| 52wk Range: | 17.06 - 42.41 |
|---|
| Volume: | 1,073,602 |
|---|
| Avg Vol (3m): | 1,537,120 |
|---|
| Market Cap: | 3.60B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.51 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Elan Rejects Royalty Offer AgainZacks(Fri, May 24)
- Royalty Pharma offer for Elan gets little supportAP(Fri, May 24)
- Royalty Pharma eases condition for Elan offerAP(Thu, May 23)
- Theravance to Present at Investor Conferences in June 2013Marketwired(Thu, May 23)
- Elan Board Unanimously Rejects $6.4 Billion Takeover Offerat Bloomberg(Thu, May 23)
- Elan rejects Royalty's $6.4 billion raised offerReuters(Thu, May 23)
- Elan rejects Royalty's $6.4 bln raised offerat Reuters(Thu, May 23)
- Royalty cuts acceptance bar for Elan bid to 50 percentat Reuters(Thu, May 23)
- Royalty cuts acceptance bar for Elan bid to 50 pctat Reuters(Thu, May 23)
- When Savvy Dealmaking Borders on Reckless Spendingat Motley Fool(Tue, May 21)
- Elan Provides Strategic UpdateZacks(Tue, May 21)
- Analysts: Microsoft Has Big Potential and 3 More Research Notes to Browseat Wall St. Cheat Sheet(Tue, May 21)
- Elan Continues To Make Baffling Strategic Decisionat Investopedia(Tue, May 21)
- THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, May 21)
- Theravance pullback on Elan bid a buying opportunity, says Piper Jaffrayat theflyonthewall.com(Tue, May 21)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 365.68 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.77 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.46 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | 0.10 |
|---|
Business Summary
Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)...
View More